// App-Quantinova.ai

107 : NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma-18 m DFS analysis.

Researchers

Presenter

  • Fernando Rivera

Principal Investigators

  • Paula Jimenez-Fonseca

  • Pilar Garcia Alfonso

  • Enrique Aranda

  • Eva Fernandez

  • Maria Alsina

  • Luis Lopez-Gomez

  • Ma Carmen Galan

  • Esther Falco

  • Jose Luis Manzano

  • Encarnacin Gonzlez

  • Monica Jorge

  • Javier Gallego

  • M. Luisa Limon

Medical Centers

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Hospital General Universitario de Elche, Alicante, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Son Llatzer, Palma De Mallorca, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon, Madrid, SpainInstitut Catala d Oncologia, Hospital Duran i Reynals, Barcelona, SpainHospital Xeral Cies, Vigo, Spain

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • Hospital de Valme, Seville, Spain

  • Hospital Virgen de la Salud, Toledo, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Capecitabine and oxaliplatin

  • Trastuzumab

  • Oxaliplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01130337

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved